

Jayme E Locke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2500405/publications.pdf>

Version: 2024-02-01

106
papers

3,597
citations

186265

28
h-index

144013

57
g-index

108
all docs

108
docs citations

108
times ranked

3283
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient survival following third time liver transplant in the United States in the MELD era. American Journal of Surgery, 2022, 223, 1206-1211.	1.8	1
2	First clinical-grade porcine kidney xenotransplant using a human decedent model. American Journal of Transplantation, 2022, 22, 1037-1053.	4.7	204
3	Donor-reported barriers to living kidney donor follow-up. Clinical Transplantation, 2022, 36, e14621.	1.6	2
4	Abnormal time-zero histology is predictive of kidney transplant outcomes. Clinical Transplantation, 2022, 36, e14676.	1.6	2
5	COVID-19 and transplantation Data censoring. American Journal of Transplantation, 2022, 22, 1958-1962.	4.7	3
6	Lost potential and missed opportunities for DCD liver transplantation in the United States. American Journal of Surgery, 2022, 224, 990-998.	1.8	2
7	A Sex-Adjusted Model for End-Stage Liver Disease Sodium Score for Equality in Liver Transplant. JAMA Surgery, 2022, , .	4.3	1
8	The science of xenotransplantation for nephrologists. Current Opinion in Nephrology and Hypertension, 2022, 31, 387-393.	2.0	1
9	Greater community vulnerability is associated with poor living donor navigator program fidelity. Surgery, 2022, 172, 997-1004.	1.9	5
10	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
11	Pig kidney xenotransplantation: Progress toward clinical trials. Clinical Transplantation, 2021, 35, e14139.	1.6	37
12	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
13	What Therapeutic Regimen Will Be Optimal for Initial Clinical Trials of Pig Organ Transplantation?. Transplantation, 2021, 105, 1143-1155.	1.0	28
14	Integrating APOL1 Kidney-risk Variant Testing in Live Kidney Donor Evaluation: An Expert Panel Opinion. Transplantation, 2021, 105, 2132-2134.	1.0	14
15	Leveraging Frailty to Mitigate Sex-Based Disparities in Access to Liver Transplant. JAMA Surgery, 2021, 156, 263.	4.3	2
16	Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation. Human Immunology, 2021, 82, 139-146.	2.4	17
17	Obesity is a risk factor for progression to kidney transplant waitlisting after liver transplantation. Clinical Transplantation, 2021, 35, e14317.	1.6	2
18	APOL1 genotyping in kidney transplantation: to do or not to do, that is the question? (contra). Kidney International, 2021, 100, 30-32.	5.2	6

#	ARTICLE	IF	CITATIONS
19	Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. <i>Kidney International Reports</i> , 2021, 6, 1788-1798.	0.8	2
20	Cognitive mapping as an approach to facilitate organ donation among African Americans. <i>Science Progress</i> , 2021, 104, 003685042110294.	1.9	1
21	Self-advocacy is associated with lower likelihood of living donor kidney transplantation. <i>American Journal of Surgery</i> , 2021, 222, 36-41.	1.8	6
22	Suggested Patient Selection Criteria for Initial Clinical Trials of Pig Kidney Xenotransplantation in the United States. <i>Transplantation</i> , 2021, 105, 1904-1908.	1.0	25
23	Obesity as an isolated contraindication to kidney transplantation in the end-stage renal disease population: A cohort study. <i>Obesity</i> , 2021, 29, 1538-1546.	3.0	11
24	Evaluation of Community-Level Vulnerability and Racial Disparities in Living Donor Kidney Transplant. <i>JAMA Surgery</i> , 2021, 156, 1120.	4.3	22
25	Hepatic macrosteatosis in the US pediatric deceased liver donor population. <i>Pediatric Transplantation</i> , 2021, , e14155.	1.0	1
26	Survival following simultaneous liver-lung versus liver alone transplantation: Results of the US national experience. <i>American Journal of Surgery</i> , 2021, 222, 813-818.	1.8	1
27	Significance and innovation: cornerstones of a successful grant application. <i>Surgery</i> , 2021, 170, 1080-1082.	1.9	1
28	Early Outcomes With the Liver-kidney Safety Net. <i>Transplantation</i> , 2021, 105, 1261-1272.	1.0	16
29	Tackling the weight list problem. <i>American Journal of Transplantation</i> , 2020, 20, 329-330.	4.7	0
30	Donor-Recipient Relationship and Risk of ESKD in Live Kidney Donors of Varied Racial Groups. <i>American Journal of Kidney Diseases</i> , 2020, 75, 333-341.	1.9	19
31	Enhanced Advocacy and Health Systems Training Through Patient Navigation Increases Access to Living-donor Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 122-129.	1.0	25
32	A Qualitative Assessment of the Living Donor Navigator Program to Identify Core Competencies and Promising Practices for Implementation. <i>Progress in Transplantation</i> , 2020, 30, 29-37.	0.7	7
33	Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?. <i>Transplantation</i> , 2020, 104, 1215-1228.	1.0	21
34	Human immunodeficiency virus from life taking to life giving: expanding the donor pool by using HIV-positive donors. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 626-630.	1.6	2
35	Commentary on: "Outcomes in Kidney Transplantation Between Veterans Affairs and Civilian Hospitals: Considerations in the Context of the MISSION Act". <i>Annals of Surgery</i> , 2020, 272, 511.	4.2	0
36	Bariatric surgery to achieve transplant in end-stage organ disease patients: A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2020, 220, 566-579.	1.8	28

#	ARTICLE	IF	CITATIONS
37	Use of Patient Navigators to Reduce Barriers in Living Donation and Living Donor Transplantation. <i>Current Transplantation Reports</i> , 2020, 7, 72-80.	2.0	2
38	Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception. <i>Journal of the American College of Surgeons</i> , 2020, 230, 503-512.e8.	0.5	1
39	Geographic Differences in Population Health and Expected Organ Supply in the Gulf Coast Region of the United States Compared to Non-Gulf States. <i>Transplantation</i> , 2020, 104, 421-427.	1.0	6
40	Quantifying Sex-Based Disparities in Liver Allocation. <i>JAMA Surgery</i> , 2020, 155, e201129.	4.3	68
41	Positive Crossmatch Kidney Transplantation: State of the Art and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2020, 26, 3460-3467.	1.9	3
42	Patient Perspectives on Weight Management for Living Kidney Donation. <i>Journal of Surgical Research</i> , 2019, 244, 50-56.	1.6	7
43	Donation approval among obese living kidney donor candidates: The impact of metabolic syndrome. <i>Surgery</i> , 2019, 166, 940-946.	1.9	7
44	Get on with it! A novel allocation strategy to reduce kidney discards. <i>American Journal of Transplantation</i> , 2019, 19, 2971-2972.	4.7	3
45	CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13494.	1.0	7
46	Obesity and long-term mortality risk among living kidney donors. <i>Surgery</i> , 2019, 166, 205-208.	1.9	26
47	Time for reform in transplant program-specific reporting: AST/ASTS transplant metrics taskforce. <i>American Journal of Transplantation</i> , 2019, 19, 1888-1895.	4.7	42
48	Kidney Transplantation in a HIV-Positive Recipient. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 614-616.	4.5	1
49	Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report. <i>Transplantation</i> , 2019, 103, 1199-1205.	1.0	26
50	Mitigating Racial and Sex Disparities in Access to Living Donor Kidney Transplantation. <i>Annals of Surgery</i> , 2019, 270, 639-646.	4.2	17
51	Center Variation and Risk Factors for Failure to Complete 6 Month Postdonation Follow-up Among Obese Living Kidney Donors. <i>Transplantation</i> , 2019, 103, 1450-1456.	1.0	5
52	Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. <i>Transplantation</i> , 2019, 103, 1425-1432.	1.0	16
53	Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus. <i>Clinical Transplantation</i> , 2019, 33, e13466.	1.6	22
54	Optimal timing of hepatitis C treatment among HIV/HCV coinfecting ESRD patients: Pre- vs posttransplant. <i>American Journal of Transplantation</i> , 2019, 19, 1806-1819.	4.7	12

#	ARTICLE	IF	CITATIONS
55	Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 815-826.	1.9	27
56	In Reply to "Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline". <i>American Journal of Kidney Diseases</i> , 2018, 72, 155.	1.9	0
57	Decreasing deceased donor transplant rates among children (≤ 6 years) under the new kidney allocation system. <i>American Journal of Transplantation</i> , 2018, 18, 1690-1698.	4.7	20
58	Landscape of ABO-Incompatible Live Donor Kidney Transplantation in the US. <i>Journal of the American College of Surgeons</i> , 2018, 226, 615-621.	0.5	20
59	Response to: Regarding "HIV protease inhibitors and mortality following kidney transplantation". <i>American Journal of Transplantation</i> , 2018, 18, 1571.	4.7	1
60	Evaluation of Kidney Donors: Core Curriculum 2018. <i>American Journal of Kidney Diseases</i> , 2018, 71, 737-747.	1.9	26
61	Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. <i>Transplant Infectious Disease</i> , 2018, 20, e12829.	1.7	13
62	Impact of the new kidney allocation system A2/A2B + B policy on access to transplantation among minority candidates. <i>American Journal of Transplantation</i> , 2018, 18, 1947-1953.	4.7	33
63	Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors. <i>Annals of Surgery</i> , 2018, 267, 1161-1168.	4.2	44
64	Urologic malignancies in kidney transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 13-22.	4.7	45
65	Long Cold Ischemia Times in Same Hospital Deceased Donor Transplants. <i>Transplantation</i> , 2018, 102, 471-477.	1.0	12
66	Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. <i>Kidney International</i> , 2018, 93, 706-715.	5.2	17
67	Can you hear me now? Patient preferences for evaluating kidney transplant centers. <i>American Journal of Transplantation</i> , 2018, 18, 2624-2624.	4.7	1
68	Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 2080-2087.	1.0	25
69	Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2483-2495.	4.7	14
70	Expand the Pool of Living Donors for Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1142-1143.	4.5	1
71	Response to "It is time to revise the kidney allocation system to restore the pediatric advantage". <i>American Journal of Transplantation</i> , 2018, 18, 2367-2367.	4.7	0
72	Survival Benefit of Kidney Transplantation in HIV-infected Patients. <i>Annals of Surgery</i> , 2017, 265, 604-608.	4.2	75

#	ARTICLE	IF	CITATIONS
73	Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)–Infected Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 173-179.	4.7	4
74	Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 467-475.	4.5	50
75	Patterns of primary care utilization before and after living kidney donation. <i>Clinical Transplantation</i> , 2017, 31, e12992.	1.6	8
76	Quantifying Postdonation Risk of ESRD in Living Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2749-2755.	6.1	150
77	Abdominal lean muscle is associated with lower mortality among kidney waitlist candidates. <i>Clinical Transplantation</i> , 2017, 31, e12911.	1.6	35
78	Survival Benefit of Transplantation with a Deceased Diabetic Donor Kidney Compared with Remaining on the Waitlist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 974-982.	4.5	32
79	The Authors Reply. <i>Kidney International</i> , 2017, 91, 1256.	5.2	0
80	Obesity increases the risk of end-stage renal disease among living kidney donors. <i>Kidney International</i> , 2017, 91, 699-703.	5.2	136
81	Impact of Protease Inhibitor–Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 3114-3122.	4.7	56
82	Apolipoprotein L1 Gene Effects on Kidney Transplantation. <i>Seminars in Nephrology</i> , 2017, 37, 530-537.	1.6	23
83	Kidney transplantation of highly sensitized recipients under the new kidney allocation system: A reflection from five different transplant centers across the United States. <i>Human Immunology</i> , 2017, 78, 30-36.	2.4	33
84	Lymphocyte–depleting induction therapy lowers the risk of acute rejection in African American pediatric kidney transplant recipients. <i>Pediatric Transplantation</i> , 2017, 21, e12823.	1.0	15
85	Long-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus–Infected Recipients. <i>Transplantation</i> , 2016, 100, 141-146.	1.0	53
86	Identification of Optimal Donor–Recipient Combinations Among Human Immunodeficiency Virus (HIV)–Positive Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2016, 16, 2377-2383.	4.7	11
87	Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 3099-3105.	0.6	9
88	Overcoming Immunologic Barriers to Kidney Transplantation: Desensitization and Paired Donation. <i>Current Surgery Reports</i> , 2016, 4, 1.	0.9	0
89	Insurance Type and Solid Organ Transplantation Outcomes: A Historical Perspective on How Medicaid Expansion Might Impact Transplantation Outcomes. <i>Journal of the American College of Surgeons</i> , 2016, 223, 611-620e4.	0.5	43
90	Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 2096-2104.	4.7	29

#	ARTICLE	IF	CITATIONS
91	A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2222-2229.	6.1	117
92	Identification of Strategies to Facilitate Organ Donation among African Americans using the Nominal Group Technique. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 286-293.	4.5	22
93	To whom goes the kidney?. <i>Liver Transplantation</i> , 2014, 20, 1017-1018.	2.4	1
94	Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA-Incompatible Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 857-863.	1.0	104
95	Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients. <i>Transplantation</i> , 2014, 97, 446-450.	1.0	83
96	Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. <i>Hepatic Medicine: Evidence and Research</i> , 2011, 3, 53.	2.5	2
97	Desensitization in HLA-Incompatible Kidney Recipients and Survival. <i>New England Journal of Medicine</i> , 2011, 365, 318-326.	27.0	604
98	Renal Transplantation in HIV-Positive Recipients. <i>Current Infectious Disease Reports</i> , 2010, 12, 71-75.	3.0	7
99	Renal Transplant in HIV-Positive Patients. <i>Archives of Surgery</i> , 2009, 144, 83.	2.2	57
100	Stem Cells and the Liver: Clinical Applications in Transplantation. <i>Advances in Surgery</i> , 2009, 43, 35-51.	1.3	8
101	ABO Incompatible Renal Transplantation: A Paradigm Ready for Broad Implementation. <i>Transplantation</i> , 2009, 87, 1246-1255.	1.0	215
102	Donor Ethnicity Influences Outcomes following Deceased-Donor Kidney Transplantation in Black Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2011-2019.	6.1	19
103	Obesity Impacts Access to Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 349-355.	6.1	213
104	Generation of Humanized Animal Livers Using Embryoid Body-derived Stem Cell Transplant. <i>Annals of Surgery</i> , 2008, 248, 487-493.	4.2	10
105	Declining Outcomes in Simultaneous Liver-Kidney Transplantation in the MELD Era: Ineffective Usage of Renal Allografts. <i>Transplantation</i> , 2008, 85, 935-942.	1.0	145
106	ABO-Incompatible Transplantation: Less May Be More. <i>Transplantation</i> , 2007, 84, S8-S9.	1.0	29